European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Changing patterns in the epidemiology of β‐thalassemia116
COVID‐19 vaccine‐associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome100
COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system90
The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management88
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy69
Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies68
Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis62
The hematologic consequences of obesity62
COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency42
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia38
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML36
Prevalence of pyruvate kinase deficiency: A systematic literature review34
Cellular immune response to acute exercise: Comparison of endurance and resistance exercise33
The changing epidemiology of the ageing thalassaemia populations: A position statement of the Thalassaemia International Federation32
Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib31
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus28
The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies28
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series27
Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view27
COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation25
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practice25
Anticoagulation strategies in extracorporeal circulatory devices in adult populations25
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire24
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis24
0.060688972473145